DEBM_CompanyBanner_InnovationFund_LG

Digital Health Investment


investing in
future
patient
care

We are the strategic investment fund of Debiopharm

Investment focus is Smart Data & Digital Health in oncology and infectious disease, with an impact on drug development and the patient journey

Company stage
Late pilot or early commercial
Investment round
Series A and B
Our initial investment
$1M - 10M
Startup funding
Our latest portfolio news
February 13, 2020

Debiopharm invests in remote cancer patient symptom monitoring for personalized care with Carevive Series C financing round

Read more
January 13, 2020

Kaiku Health welcomes Professor Vesa Kataja as new Chief Medical Officer

Read more
See all news

Business

Discover our Portfolio

Our current and past investments

Discover

At a glance

Our mission

Our objective is to make strategic investments in innovative companies with technologies and business models that change the way we develop drugs and treat patients.

We bring value to our portfolio companies through our knowledge in medicine, pharmaceutical development, regulatory/reimbursement aspects, management and expertise in bringing products to market. We drive our portfolio investments to successful exits.

Our objectives

  • 2-3 new investments per year
  • Active involvement to help portfolio companies develop
  • Long term value creation

Our investment criteria

  • Strong management team
  • Ambitious vision
  • Innovative technology
  • Robust execution plan

History

  • Over 100 million invested since 2008
  • Cumulative equity raised by all companies: USD 500 million
  • We led 12 out of the 15 last investment rounds
  • Portfolio company achievements: 18 FDA clearances or CE marks, 2 IPOs
Debiopharm-Tanja-Dowe
Leadership team

Discover the people who guide and bring long-term vision to the digital health investments at Debiopharm

Leadership Team
Startup funding

Are you a startup looking for funding? Discover our criteria investment in Smart Data & Digital Health

Discover